Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 2Lung Neoplasms 2Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neurofibromatosis 1 1Neuroblastoma 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Carcinoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK-positive NSCLC 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × lorlatinib × Clear all
NCT04753658 2024-09-23

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Pfizer

Terminated
15 enrolled 22 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡